The Efficacy and Safety of Inclisiran for Low-Density Lipoprotein (LDL) in Patients With Atherosclerotic Cardiovascular Disease (ASCVD): A Systematic Review of Randomized Controlled Trials.

Autor:	Mirghani H; Internal Medicine, University of Tabuk, Tabuk, SAU., Albalawi BH; Surgery, King Khalid Hospital, Tabuk, SAU., Alshehri MS; Medicine, University of Tabuk, Tabuk, SAU., Almalawi WM; Internal Medicine, King Fahad Hospital (KFH), Tabuk, SAU., Alanezi S; Medicine and Surgery, University of Tabuk, Tabuk, SAU., Alarki M; College of Medicine, University of Tabuk, Tabuk, SAU., Alyahya AA; Medicine, University of Tabuk, Tabuk, SAU., Alshaman S; Medicine, University of Tabuk, Tabuk, SAU., Shaman MS; Medicine and Surgery, University of Tabuk, Tabuk, SAU., AlAnazi A; Medicine, College of Medicine, Tabuk University, Tabuk, SAU.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2024 Sep 28; Vol. 16 (9), pp. e70411. Date of Electronic Publication: 2024 Sep 28 (Print Publication: 2024).
DOI:	10.7759/cureus.70411
Abstrakt:	This systematic review synthesizes current evidence to evaluate the safety and efficacy of inclisiran for lowering low-density lipoprotein cholesterol (LDL-C). A thorough search was conducted across four main databases - PubMed, Web of Science, SCOPUS, and Science Direct - for relevant studies published in the literature within the last five years (2020-2024). We included seven studies with a total of 6831 participants, of which 4661 (68.2%) were males. The follow-up duration ranged from 60 to 1350 days. The intervention we focused on was a subcutaneous injection of inclisiran (284 mg) in the seven trials. Of the total population, 2411 (35%) had diabetes mellitus (DM) and 5335 (78.1%) had hypertension (HTN). The seven trials documented a significant reduction in the mean LDL-C level following the inclisiran application. Early inclisiran administration recorded better results. Inclisiran was found to be efficient, safe, and tolerable among atherosclerotic cardiovascular disease (ASCVD) patients. An inclisiran regimen of 284 mg proved to be efficacious and safe for reducing ASCVD. Most of the affected participants were males and hypertensive. Our findings highlight the need for additional clinical trials to examine inclisiran's safety and effectiveness with regard to cardiovascular outcomes. Extended surveillance studies may yield deeper insights into the efficacy, durability, and tolerability of inclisiran. Competing Interests: Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Mirghani et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu